SXI Life Sciences
7.548,55
PKT
-6,03
PKT
-0,08
%
Werbung
Analysen zu SXI Life Sciences-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 15.04.05 | Roche Buy | SES Research | |
| 13.04.05 | Lonza Reduce | Sarasin Research | |
| 13.04.05 | Novartis Neutral | Sarasin Research | |
| 11.04.05 | Lonza Overweight | JP Morgan | |
| 08.04.05 | Novartis Accumulate | Helvea | |
| 07.04.05 | Lonza Reduce | Sarasin Research | |
| 06.04.05 | Roche Buy | Helvea | |
| 29.03.05 | Siegfried Sector Perform | Vontobel | |
| 29.03.05 | Roche Buy | Sarasin Research | |
| 24.03.05 | Roche Sector Outperform | Vontobel | |
| 23.03.05 | Kuros (Kuros Biosciences) Sector Outperform | Vontobel | |
| 22.03.05 | Siegfried Neutral | Helvea | |
| 22.03.05 | Roche Buy | Sarasin Research | |
| 21.03.05 | Novartis Neutral | Sarasin Research | |
| 21.03.05 | Novartis Kaufen | Helaba Trust | |
| 22.03.05 | Novartis Accumulate | Helvea | |
| 21.03.05 | Novartis Neutral | Sarasin Research | |
| 21.03.05 | Tecan (N) Sector Perform | Vontobel | |
| 17.03.05 | Roche In-Line | Goldman Sachs | |
| 17.03.05 | Novartis Outperform | Goldman Sachs | |
| 17.03.05 | Tecan (N) Reduce | Helvea | |
| 17.03.05 | Roche Buy | Helvea | |
| 11.03.05 | Novartis Neutral | Sarasin Research | |
| 11.03.05 | Novartis Buy | Helvea | |
| 10.03.05 | Novartis Neutral | Sarasin Research | |
| 10.03.05 | Roche Buy | Sarasin Research | |
| 09.03.05 | Novartis Buy | Merrill Lynch | |
| 07.03.05 | Roche Neutral | Helvea | |
| 08.03.05 | Novartis Neutral | Sarasin Research | |
| 08.03.05 | Roche Neutral | Helvea | |
| 01.03.05 | Roche Buy | Sarasin Research | |
| 24.02.05 | Novartis Overweight | Lehman Brothers | |
| 22.02.05 | Novartis Buy | Helvea | |
| 23.02.05 | Novartis Outperform | Goldman Sachs | |
| 21.02.05 | Straumann Outperform | Goldman Sachs | |
| 21.02.05 | Novartis Neutral | Sarasin Research | |
| 22.02.05 | Novartis Akkumulieren | Independent Research | |
| 21.02.05 | Novartis Buy | Helvea | |
| 22.02.05 | Novartis Hold | SEB | |
| 22.02.05 | Novartis Kaufen | Helaba Trust |